Compare Moderna, Inc. (MRNA) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $60.77 (market cap $3.39B). The key difference: Moderna, Inc. is far larger — about 23.2× SP Funds S&P 500 Sharia Industry Exclusions ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, SP Funds S&P 500 Sharia Industry Exclusions ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and SP Funds S&P 500 Sharia Industry Exclusions ETF for 64 Days on average.
| MRNA | SPUS | |
|---|---|---|
Market Cap | $78.65B | $3.39B |
Volume | 37,373,437 | 349,184 |
Sector | Health | Broad Market / Factor |
52-Week High | $203.46 | $61.15 |
52-Week Low | $22.36 | $46.65 |
Typical Hold Time | 59 Days | 64 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
SPUS (SP Funds S&P 500 Sharia Industry Exclusions ETF) trades at $60.77, down 0.49% with a bearish short-term technical signal despite bullish moving averages. The ETF shows consistent dividend distributions of $0.03 per share. Technical indicators show mixed signals with RSI suggesting overbought conditions while ADX indicates strong trend momentum.
The ETF faces headwinds from significant short interest growth (174.5% increase in September 2026) while maintaining its Sharia-compliant investment strategy. Key risks include market volatility and sector concentration, though the S&P 500 exposure provides diversification benefits for investors seeking compliant equity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
